Curve Therapeutics appoints Dr Sally Price as Vice President of Biology
- Dr Price brings over 20 years of experience in drug discovery and development, across pharma and biotech
Southampton, UK, 18 September 2023 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a game-changing, functional drug discovery platform, today announces the appointment of Dr Sally Price as its Vice President of Biology.
Dr Price joins from Evox Therapeutics, where she held the position of Senior Director of Translational Science. Over the course of a decorated 20-year career in drug development and discovery, Dr Price began at AstraZeneca, working her way up to Associate Director of Drug Safety and Metabolism in 2015. During Covid-19, Dr Price took secondment from her position as Head of Cell and Translational Science at Medicines Discovery Catapult to establish the Alderley Park Lighthouse Laboratories for Covid-19 testing.
Simon Kerry, PhD, MBA, Chief Executive Officer of Curve Therapeutics, said: “We are thrilled to welcome Sally to the team as we progress our lead cancer assets, all with first-in-class potential, into the clinic. Her extensive experience in drug discovery and development across both biotech and pharma complements the skillset of our existing leadership team, further enhancing Curve’s credentials as a leading drug discovery biotech company.”
Dr Sally Price, Vice President of Biology at Curve Therapeutics, added: “I am pleased to be joining Curve at such an important time, and look forward to working with such a successful and dynamic leadership team as we advance Curve’s revolutionary Microcycle discovery platform. I am confident that my experience in drug discovery and development will prove beneficial in utilising this powerful platform, screening intracellularly for biologically active molecules against targets which are conventionally elusive.”
-ENDS-
For more information, please contact:
Curve Therapeutics
Simon Kerry
Chief Executive Officer
info@curvetx.com
Optimum Strategic Communications
Mary Clark, Vici Rabbetts
+44 (0) 208 078 4357
curve@optimumcomms.com
About Curve Therapeutics
Curve Therapeutics (Curve) is a private biotechnology company pioneering a game-changing, functional drug discovery platform to generate higher quality hits and leads with the aim of discovering first-in-class therapeutics. Curve originated from world-leading Microcycle® research conducted by Professor Tavassoli’s group in the Department of Chemistry at the University of Southampton, UK. Curve has developed an IP-protected, mammalian cell platform technology for functional screening and enrichment of diverse hexameric cyclic peptide Microcycle® libraries to identify those library members that have the desired biological activity against a therapeutic target. Curve’s platform enables the discovery of biologically active molecules against targets that have evaded conventional drug discovery techniques. A key advantage of the technology is that both the library and the target are present in all of their native conformations within a cell. Uniquely, the compact size and rigid structure of Microcycle® enables the design of small molecule hits and leads. The platform can be used for a wide range of therapeutically relevant targets, including protein-protein and protein-DNA interactions and has been used by Curve to develop a pipeline of cancer programmes against targets including a dual HIF-1/HIF-2 inhibitor. Based in Southampton, Curve was established in 2019 by founding investor Advent Life Sciences and subsequently joined by Epidarex Capital. In 2022, the company announced a US$1.7bn global research collaboration with MSD the trade name of Merck & Co., Inc., Kenilworth, NJ USA, to discover and validate modulators of up to five therapeutic targets using its Microcycle® technology, initially for oncology and neurology indications. For more information visit: www.curvetx.com.
